Get started
KNIGHT THERAPEUTICS INCKNIGHT THERAPEUTICS INCKNIGHT THERAPEUTICS INC

KNIGHT THERAPEUTICS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

GUD chart


Full chart

GUD upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪570.83 M‬ CAD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
130.45
Basic EPS (TTM)
0.04 CAD
Net income (FY)
‪4.33 M‬ CAD
Revenue (FY)
‪371.30 M‬ CAD
Shares float
‪69.24 M‬
Beta (1Y)
0.38

Employees


Employees (FY)
745
Change (1Y)
+20 +2.76%
Revenue / Employee (1Y)
‪498.39 K‬ CAD
Net income / Employee (1Y)
‪5.81 K‬ CAD

About KNIGHT THERAPEUTICS INC


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Samira Sakhia
Website
gud-knight.com
Headquarters
Montréal
Founded
2013
FIGI
BBG006373G71
Knight Therapeutics, Inc. engages in the business of acquiring, in licensing, out-licensing, marketing, and commercializing pharmaceuticals products. The firm also focuses on building a portfolio of innovative products through in-licensing or acquiring product rights. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montréal, Canada.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

GUD news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as GUD.

Frequently Asked Questions


The current price of GUD is 5.72 CAD — it has decreased by −0.35% in the past 24 hours. Watch KNIGHT THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSX exchange KNIGHT THERAPEUTICS INC stocks are traded under the ticker GUD.
GUD stock has risen by 4.00% compared to the previous week, the month change is a −6.38% fall, over the last year KNIGHT THERAPEUTICS INC has showed a −0.69% decrease.
We've gathered analysts' opinions on KNIGHT THERAPEUTICS INC future price: according to them, GUD price has a max estimate of 10.00 CAD and a min estimate of 6.45 CAD. Watch GUD chart and read a more detailed KNIGHT THERAPEUTICS INC stock forecast: see what analysts think of KNIGHT THERAPEUTICS INC and suggest that you do with its stocks.
GUD reached its all-time high on Dec 5, 2016 with the price of 11.03 CAD, and its all-time low was 3.51 CAD and was reached on Mar 3, 2014. View more price dynamics on GUD chart.
See other stocks reaching their highest and lowest prices.
GUD stock is 1.59% volatile and has beta coefficient of 0.38. Track KNIGHT THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is KNIGHT THERAPEUTICS INC there?
Today KNIGHT THERAPEUTICS INC has the market capitalization of ‪568.85 M‬, it has increased by 1.16% over the last week.
Yes, you can track KNIGHT THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
KNIGHT THERAPEUTICS INC is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
GUD earnings for the last quarter are 0.11 CAD per share, whereas the estimation was 0.018 CAD resulting in a 515.11% surprise. The estimated earnings for the next quarter are 0.0054 CAD per share. See more details about KNIGHT THERAPEUTICS INC earnings.
KNIGHT THERAPEUTICS INC revenue for the last quarter amounts to ‪94.07 M‬ CAD, despite the estimated figure of ‪87.67 M‬ CAD. In the next quarter, revenue is expected to reach ‪87.76 M‬ CAD.
GUD net income for the last quarter is ‪10.73 M‬ CAD, while the quarter before that showed ‪85.00 K‬ CAD of net income which accounts for ‪12.53 K‬% change. Track more KNIGHT THERAPEUTICS INC financial stats to get the full picture.
No, GUD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 17, 2025, the company has 745 employees. See our rating of the largest employees — is KNIGHT THERAPEUTICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KNIGHT THERAPEUTICS INC EBITDA is ‪60.51 M‬ CAD, and current EBITDA margin is 16.33%. See more stats in KNIGHT THERAPEUTICS INC financial statements.
Like other stocks, GUD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KNIGHT THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So KNIGHT THERAPEUTICS INC technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating KNIGHT THERAPEUTICS INC stock shows the buy signal. See more of KNIGHT THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.